Form 4: Tourmaline Bio Director Sells Shares in Merger

Tourmaline Bio Director Aaron Kantoff disposed of all common stock and cashed out stock options following the company's acquisition by Novartis AG for $48.00 per share.

Summary

• Aaron Kantoff, a Director of Tourmaline Bio, Inc. (TRML), reported the disposal of all his beneficially owned common stock and derivative securities.
• The transactions occurred on October 28, 2025, pursuant to the Agreement and Plan of Merger dated September 8, 2025.
• Novartis AG, through its subsidiary Torino Merger Sub Inc., completed a cash tender offer to acquire all outstanding shares of Tourmaline Bio, Inc. common stock.
• Each common share was acquired for $48.00 in cash.
• Kantoff disposed of 88,281 shares of common stock.
• Employee stock options with exercise prices of $13.91 (10,000 shares) and $18.73 (16,800 shares) were canceled and converted into a cash payment equal to the difference between the merger consideration and the exercise price, multiplied by the number of shares.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person and shareholders who received a cash payout for their shares and options as a result of the acquisition. It represents a successful exit for the company's public shareholders.

Positives

• Shareholders, including Director Aaron Kantoff, received a cash payout of $48.00 per share, representing a clear exit strategy and liquidity.
• Stock option holders received cash for the in-the-money value of their options, providing a financial benefit from the acquisition.

Negatives

• Tourmaline Bio, Inc. ceases to be an independent publicly traded entity, eliminating future investment opportunities in the company's standalone growth.
• Shareholders will not participate in any potential future upside of the company under Novartis AG's ownership beyond the $48.00 per share merger consideration.

Risks

• The filing, being a post-transaction report, does not detail specific risks for the company or its shareholders, as the merger has already been completed.

Future Outlook

The filing reports a completed acquisition, meaning Tourmaline Bio, Inc. will no longer operate as an independent public entity. No forward-looking statements for the acquired company are provided.

Industry Context

This transaction reflects a consolidation event within the biotechnology or pharmaceutical industry, where a larger entity (Novartis AG) acquires a smaller company (Tourmaline Bio, Inc.) likely for its assets, pipeline, or strategic capabilities. Such acquisitions are common for growth and portfolio expansion in the sector.

Comparison to Industry Standards

• This Form 4 reports a specific insider transaction resulting from a completed merger and does not provide financial performance data or operational metrics that can be directly compared to industry standards or global benchmarks for company performance.
• The valuation of $48.00 per share would typically be assessed against comparable M&A transactions in the biotech sector, but the filing does not provide the necessary details for such an analysis.

Stakeholder Impact

• Shareholders: Received $48.00 in cash per share, providing liquidity and a defined return on investment.
• Employees (with options): Those holding in-the-money stock options received a cash payout, monetizing their equity incentives.
• Company (Tourmaline Bio, Inc.): Ceases to exist as an independent public entity, becoming part of Novartis AG.

Next Steps

• The filing does not detail any future actions, events, or milestones for the director or the acquired entity, as the reported transaction signifies the completion of the merger.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis AG, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Cash Tender Offer